Open Access

Impact of two mycotoxins deoxynivalenol and fumonisin on pig intestinal health

  • Alix Pierron1, 2,
  • Imourana Alassane-Kpembi1 and
  • Isabelle P. Oswald1Email author
Porcine Health Management20162:21

https://doi.org/10.1186/s40813-016-0041-2

Received: 4 March 2016

Accepted: 25 July 2016

Published: 14 September 2016

Abstract

Mycotoxins are secondary metabolites of fungi that grow on a variety of substrates. Due to their high consumption of cereals and their sensitivity, pigs are highly impacted by the presence of mycotoxins. At the European level, regulations and recommendations exist for several mycotoxins in pig feed. Among these toxins, fumonisin B1 (FB1), and deoxynivalenol (DON) have a great impact on the intestine and the immune system. Indeed, the intestine is the first barrier to food contaminants and can be exposed to high concentrations of mycotoxins upon ingestion of contaminated feed. FB1 and DON alter the intestinal barrier, impair the immune response, reduce feed intake and weight gain. Their presence in feed increases the translocation of bacteria; mycotoxins can also impair the immune response and enhance the susceptibility to infectious diseases. In conclusion, because of their effect on the intestine, FB1 and DON are a major threat to pig health, welfare and performance.

Keywords

Pig Fumonisin B1 Deoxynivalenol Feed contamination Intestine Barrier function Immune response

Background

Food safety is a major issue throughout the world. In this respect, much attention needs to be paid to the possible contamination of food and feed by fungi and the risk of mycotoxin production. Mycotoxins are secondary metabolites produced by filamentous fungi, mainly by species from the genus Aspergillus, Fusarium and Penicillium. They are produced on a wide variety of substrates before, during and after harvest. Mycotoxins are very resistant to technological treatments and difficult to eliminate; therefore they can be present in human food and animal feed [1]. The ingestion of mycotoxin-contaminated feed can induce acute diseases, and the ingestion of low doses of fungal toxins also causes damage in case of repeated exposure [2, 3].

Monogastric livestock, pig and poultry, are particularly vulnerable to mycotoxins because of the high percentage of cereals in their diet and because they lack a rumen with a microbiota able to degrade mycotoxins before their intestinal absorption. From an intestinal pig health perspective, the most notorious mycotoxins (Fig. 1) are fumonisins, especially fumonisin FB1 (FB1) and trichothecenes, especially deoxynivalenol (DON) [4]. In the European Union, some recommendations exist for both toxins in pig feed (Table 1).
Fig. 1

Chemical structure of Fumonisin B1 and Deeoxynivalenol. These two mycotoxins belong to different families, with many different chemical structures and so various effects induced

Table 1

Recommendations for DON and FB1 in pigs feed and feedstuffs. Depending of the mycotoxin and the type of feed intended to pigs, different directive and recommendation exist about the concentration authorized. (EC Recommendations 2006/576/EC and 2013/165/EU)

Mycotoxins

Pig feeds

Max. content mg/Kg (ppm)

DON

Cereals (without maize by-products)

8 (12)

Complete and complementary feeding stuffs for pigs

0.9

FB1 + FB2

Cereals

60

Complete and complementary feeding stuffs for pigs, horse and rabbit

5

This review will summarize the effect of FB1 and DON on the intestine and analyze the consequences in terms of pig health.

Toxicity of DON and FB1

Toxicity of DON

DON is a 12,13-epoxy-3α,7α,15-trihydroxytrichothec-9-en-8-on (Fig. 1). Numerous studies bring information on the toxic effects of DON in mamals, especially rodents [57]. At the molecular level, DON targets the ribosome. It binds to the A-site of the peptidyl transferase center (PTC) of this organelle [8]. This binding is linked to the epoxy- and C3- group of the DON molecule [9]. Interaction with the ribosome leads to an inhibition of the elongation of chain elongation step of protein synthesis leading to an inhibition of RNA, DNA and protein synthesis [6]. This ribosome binding activates several ribosome-associated mitogen activated protein kinases (MAPKs), including p38, c-Jun N-terminal Kinase (JNK), and extracellular signal-regulated kinase 1 and 2 (ERK1/2), an effect called “ribotoxic stress” response [10].

A high concentration DON causes effects and symptoms similar to those observed during an exposure to ionizing radiation, such as abdominal distress, salivation, discomfort, diarrhea, vomiting, leukocytosis and gastrointestinal bleeding. This mycotoxin also has high emetic and anorexic effects resulting in growth suppression [11, 12]. The colloquial name of DON is “vomitoxin” due to its strong emetic effects observed in pigs [13]. The underlying mechanisms for anorexia are not yet fully understood. Two major mediators of DON-induced anorexia, i.e. pro-inflammatory cytokines and satiety hormones, have emerged from studies carried out mainly in mice [10, 14]. It is worth to point out that, contrary to humans or pigs, emesis cannot occur in rodents, but the abnormal food intake behaviour observed in mice (or other rodents) is considered indicative of nausea-induced anorexia [6].

The immune system is sensitive to DON and can be either stimulated or suppressed depending on dose, exposure frequency, timing and the functional immune assay being employed [10]. Leukocytes, most notably mononuclear phagocytes, play a likely central role in the acute and chronic toxicity evoked by DON. Low concentrations of DON induce expression of early response and pro-inflammatory genes at the mRNA and protein levels, while high concentrations promote rapid onset of leukocyte apoptosis. This immune dysregualtion is a consequence of the ribotoxic stress. Indeed, activation of p38 and ERK1/2 triggers two competing signaling pathways, one down-stream of p38 favoring apoptosis and one downstream of ERK1/2 favoring survival and cytokine expression [6]. DON also impairs humoral and cell-mediated responses, alters serum IgA levels, IgA-associated nephropathy [15].

Others studies show, that DON can also have reproductive and teratological effects, with increase of skeletal abnormalities, neural arch defects or fusion, and genotoxic effects with the induction of oxydative stress mediated DNA damage on cells [16]. By contrast, there is inadequate evidence in experimental animals for the carcinogenicity of DON and the International Agency for Research on Cancer (IARC), placed DON in Group 3, “not classifiable as to its carcinogenicity to humans”.

Toxicity of FB1

Fumonisin B1 (FB1) is the diester of propane-1,2,3-tricarboxylic acid and 2-amino-12,16-dimethyl- 3,5,10,14,15-pentahydroxyeicosane (Fig. 1). Its toxicity have been broadly reviewed [17, 18]. The primary amine function and the tricarballylic acid side chains appears necessary for the biological activity of FB1, as N-substituted fumonisin and hydrolized fumonisin fail to elicit effects both in vitro and in vivo [19, 20]. FB1 has an unsubstituted primary amino group at C2 and competitively inhibits ceramide synthase, which results in disruption of the de novo biosynthesis of ceramide and alteration of the sphingolipid metabolism. An immediate consequence of the ceramide synthase inhibition is accumulation of the enzyme’s substrates sphinganine (Sa) and, to a lesser degree, sphingosine (So) in tissues, serum, and urine. In facts, increase in the Sa:So ratio in tissues and bio-fluids are explored as biomarker to fumonisin exposure in several species though these modifications of sphingoid base profiles are transient [21, 22].

A correlation between the fumonisin-induced Sa accumulation and the onset of apoptosis and mitosis has been shown in the liver and kidney of several species including pig [23, 24]. Moreover, the depletion of specific sphingolipids associated to the membrane lipid rafts involved in folate transport was suggested as the mechanism by which FB1 disrupts the 5-methyltetrahydrofolate uptake in cells [25]. The primary consequence of the disrupted folate uptake may be the teratogenic effect reported with FB1 given intraperitoneally to pregnant dams leading to neural tube defects in embryo [26]. Folate deficiency as a risk factor for neural tube defects is well established [27]. Besides the neural tube defects in newborns, the symptoms induced by FBs are unusually broad and include, brain lesions in horses, lung edema in swine as well as cancer in experimental animals. The International Agency for Research on Cancer (IARC) classified FB1 in Group 2B as ‘possibly carcinogenic to humans’.

Especially in pigs, fumonisins are poorly absorbed from the gastrointestinal tract. The calculated bioavailability for FB1 was approximately 0.041 of the dose [28]. The absorbed fraction remains in the tissues (preferentially in liver and kidneys) for an extended period of time, and enterohepatic recirculation contributes to the long biological half-life of the mycotoxin [28, 29].

The fumonisin toxicosis in pig is well documented. Historically, outbreaks of a fatal disease in pigs fed Fusarium verticillioides-contaminated maize crop in mid-western and south-eastern USA in 1989 led to the identification of FB1 as the causative agent of porcine pulmonary edema (PPE) [30]. Within 4–7 days of initial feeding of highly contaminated feed, pigs show respiratory distress and cyanosis that is rapidly followed by death due to acute pulmonary edema and hydrothorax [31]. Non-lethal pulmonary edema has also been reported following longer term, lower dose exposures [32]. The fumonisin-induced pulmonary edema appears to result from acute left-sided heart failure, as FB1 has been shown to decrease cardiac contractility, mean systemic arterial pressure, heart rate and cardiac output, and increases mean pulmonary artery pressure and pulmonary artery wedge pressure [33, 34]. This cardiotoxicity was also documented in horse following intraveinous administration of purified FB1 [35].

Additional findings reported in pig from chronic exposure studies include right ventricular hypertrophy due to pulmonary hypertension, hepatic injury characterized by icterus with severe hepatic fibrosis and nodular hyperplasia and effects on both specific and non-specific immunity [36, 37]. FB1 decreased phagocytosis and inhibited sphingolipid biosynthesis in pig pulmonary macrophages, and decreased clearance of particles and bacteria from the pulmonary circulation [38, 39].

Regarding the immunity, dietary exposure to FB1, even at low doses is associated to sex-specific decrease of antibody titers following vaccination and increased swine susceptibility to opportunistic pathogens [40, 41]. Of note, gender-dependent immunosuppression following subacute exposure to FB1 has also been described in mice, and the authors hypothetized that the selective alterations in lymphocyte functions and dramatic reduction in specific thymocytes in females may be related to FB1-induced alterations in estrogen metabolism and signaling [42].

Effects of DON and FB1 on the pig intestine

The toxicity of DON and FB1 varies according to several parameters such as the dose, the duration of exposure, the age and the sex of the animal, as well as nutritional factors [4345]. Their effects on performance are greater in males and young pigs [41, 45].

The intestinal tract is the first target for mycotoxins following ingestion of contaminated feed. The intestinal epithelium is a single layer of cells lining the gut lumen that acts as a selective filter, allowing the absorption of dietary nutrients, essential electrolytes, and water from the intestinal lumen into the blood circulation [46]. It also constitutes the largest and most important barrier to prevent the passage of harmful intraluminal substances from the external environment into the organism, including foreign antigens, microorganisms, and their toxins [47, 48]. Following the ingestion of mycotoxin-contaminated feed, intestinal epithelial cells may be exposed to high concentrations of toxins, potentially affecting intestinal functions [4951].

Effect on Feed intake

DON and to a letter extend FB1 have an effect on feed intake and subsequent animal growth.

The colloquial name of DON, vomitoxin, refers to its emetic effect observed both in field reports and in experimental intoxications where high doses of the toxin were given orally or intravenously to pigs. Complete feed refusal was observed at levels of 12 and vomiting at 20 mg DON/kg feed. Pig feeding trials with naturally or artificially contaminated diets have shown decreased feed consumption and weight gain at doses from 0.6 to 3 mg DON/kg feed [52]. A meta-analysis showed that deoxynivalenol reduced feed intake and weight gain by 26 %; the same analysis also demonstrated a 16 % reduction of feed intake in response to aflatoxin B1 (AFB1) [45].

Consumption of pure FB1 or FB1-contaminated feed also induces a slight reduction of feed intake and body weight in piglets. Although FB1 is poorly absorbed and metabolized in the intestine, it induces intestinal disturbances (abdominal pain or diarrhea) and cause extra-intestinal organ pathologies [53].

Effect on intestinal digestion and nutrient absorption

At the molecular level DON and FB1 have been shown to alter the absorptive functionality of the intestine.

The sodium-glucose dependent transporter (SGLT-1) activity is particularly sensitive to DON. SGLT-1 is the main apical transporter for active glucose uptake in the small intestine [54]. Inhibition of SGLT-1 by DON has nutritional consequences and could explain diarrhea associated with DON ingestion, since this transporter is responsible for daily absorption of water in the gut [5]. DON not only impairs the intestinal absorption of sugars (glucose and fructose), but also alters the uptake of palmitate and monocarboxilates in the jejunum [55].

In contrast to DON, sodium-dependent glucose absorption is up-regulated in pig after acute or long term exposure to FB1 [56, 57]. Pigs consuming corn culture extracts containing FB also showed a markedly lowered activity of aminopeptidase N [56]. Likewise, exposure to 1.5 mg/kg b.w. FB1 has been shown to induce sphingolipid depletion in pig intestinal epithelium, which can result in a deficiency of folate uptake [50, 58].

Effect on intestinal histomorphology

Consumption of mycotoxin-contaminated feed induces histological damage on intestinal tissue. Epithelial lesions (multifocal atrophy, villi fusion, apical necrosis of villi, vacuolation of enterocytes and edema of lamina propria) in the intestine of pigs fed with a diet naturally contaminated with DON have been observed [52, 59]. No effect was observed on crypt depth. Jejunal lesions, including shortened and coalesced villi, lysis of enterocytes, and edema, were also observed in an ex-vivo model of intestinal tissues after exposure to DON [6062]. Exposure to FB also induces changes in intestinal villi morphology such as reduced villi height and villi fusion and atrophy [52]. As described in poultry, the morphological changes may lead to a decrease of nutrients absorption by enterocytes, a reduced energy and nutrient uptake and impaired growth [63].

Effect on barrier function

Both DON and FB1 alter intestinal barrier functions. Several studies have investigated the effect of DON on the transepithelial electrical resistance (TEER), a good indicator of the integrity of the barrier function. DON decreases TEER in pig intestinal epithelial cells in a time and dose dependant manner [9, 51, 60, 64]. In piglets jejunal explants the paracellular passage, assessed in Ussing chambers, was significantly increased in presence of 20 to 50 μM of DON [65]. Similarly to DON, FB1 impaired the integrity of porcine intestinal epithelial cell line derived from the jejunum (IPEC-J2) monolayer via altered viability and reduced TEER [66]. It has also been observed that a prolonged exposure to FB1 prevents the establishment of the TEER and alters the resistance of an already established monolayer of porcine intestinal epithelial cells [67].

At the molecular level, these toxins affect the intestinal epithelium permeability through modulation of the tight junction complexes [50, 51]. A defective expression of occludin and E-cadherin has been observed in the ileum of piglets fed low doses of FB1 [61]. The FB-induced alteration of the sphingolipid biosynthesis pathway and the associated lipid rafts could also contribute to impairing the establishment and maintenance of tight junctions [53]. Likewise, the activation of MAPKs by DON affects the expression and cellular localization of proteins forming or being associated with tight junctions such as claudins and ZO-1, which results in increased intestinal paracellular permeability [60].

The loss of tight junction integrity and resulting increased paracellular permeability may lead to increased bacterial translocation across the intestine and increased susceptibility to enteric infections. Such an increase in bacterial passage through intestinal epithelial cells has major implications for pig health in terms of sepsis, inflammation and enteric infection.

Differentiated IPEC-J2 cells treated 24 h with 0.1-10 μM DON in a co-exposure with Salmonella Typhimurium bacteria show a significant increase of the translocation of the bacteria across intestinal epithelial cells [68]. On differentiated IPEC-1 cells treated 48 h with DON an increase translocation of Escherichia coli was observed in 17, 50 and 63 % with 5, 10 and 20 μM DON respectively [65]. So, DON is able to increase the passage of macromolecule and bacteria in intestinal epithelial cells.

Two separate studies analyzed the effect of low to moderate doses of FB1 on intestinal colonization and mucosal response to pathogenic strains of E. coli [69, 70]. They both demonstrated a higher susceptibility of intestinal E. coli infection of piglets exposed to the toxin. Translocation of bacteria to the mesenteric lymph nodes and dissemination to the lungs, and to a lesser extent to liver and spleen, were observed in FB1-treated pigs in comparison to untreated animals [70].

Modulation of intestinal immune response

DON and FB1 impact the systemic and/or the local immune response (review [5, 10, 53]). As far as pig is concerned, several studies have investigated the effect of theses mycotoxins on the intestinal immune system.

The effect of ingestion of FB1 was measured on the intestinal production of 5 inflammatory cytokines (IL-1β, IL-6, IL-12, TNF-β and IL-8). Both in vitro and in vivo data indicate that FB1 specifically decreases expression of IL-8 mRNA [71]. IL-8 being involved in the recruitment of inflammatory cells in the intestine during infection [7274], this specific decrease of intestinal IL-8 may contribute to the observed increased susceptibility of FB1-treated piglets to E. coli infection [70]. The increased susceptibility to intestinal infection is also correlated with a reduced intestinal expression of IL-12p40, an impaired function of intestinal antigen presenting cells (APC), a decreased upregulation of Major Histocompatibility Complex Class II molecule (MHC-II) and reduced T cell stimulatory capacity [69].

DON modulates intestinal immunity both directly (through activation of signalling pathways) and indirectly (through crossing of luminal bacterial antigens, which was observed together with bacterial translocation following mucus layer alteration and tight junction opening) [75]. In a pig jejunal explant model, DON has been shown to trigger the innate as well as adaptative immunity [76]. Intestinal exposure to DON induced a pro-inflammatory response with a significant increase of expression of TNF-α, IL-1α, IL-1β, and IL-8. Moreover, DON up-regulated the expression of genes involved in the differentiation of Th17 cells (STAT3, IL–17A, IL-6, IL-1b) at the expenses of the pathway of regulatory T cells (FoxP3, RALDH1). DON also induced genes related to the pathogenic Th17 cells subset such as IL–23A, IL-22 and IL-21 and not genes related to the regulatory Th17 cells such as TGF-b and IL-10 [76]. Likewise, DON potentiated the up-regulation of IL-1β, IL-8, MCP1 and IL-6 induced by S. Typhimurium in pig intestinal loops [68].

Intestinal microbiota

As other fungi secondary metabolites especially antibiotics, several mycotoxins have demonstrated antimicrobial properties [77, 78]. As a consequence, mycotoxins may modify the intestinal microflora. Surprisingly, this impact of mycotoxins has been poorly investigated. Two studies have investigated the impact of DON and FB1 on the intestinal microflora [79, 80].

The first study investigated the impact of DON on the intestinal microflora by Capillary Electrophoresis Single-Stranded Conformation Polymorphism (CE-SSCP). Consumption of feed naturally contaminated with DON (2.8 mg/kg feed) for four weeks had a moderate effect on total faecal Aerobic Mesophilic Bacteria and Anaerobic Sulfite-Reducing. By constrast, DON changed the faecal microflora balance; it did not impact the diversity index but modulate the richness index [79].

In the second study, pigs received feed contaminated with 12 mg FB/kg feed for 63 days. This diet transiently affected the balance of the digestive microbiota during the first four weeks of exposure as measured by SSCP feacal microbiota profiles; a co-infection with S. typhimurium amplified this phenomenon and change the microbiota profile. As already observed with DON, aerobic mesophylic bacteria count was not change by FB1 treatment [80].

Conclusion

Regulations and recommendations exist for six mycotoxins (AF, FB, Ochratoxin A (OTA), zearalenone (ZEN), T2/HT2 toxins (T2/HT2) and DON) present in pig feed. Among them, DON and FB have been studied for their toxicity in the intestine of pig. The intestine is a target for mycotoxins and as illustrated in this paper, the fact that the intestine is a target for DON and FB1 have some consequences in terms of pig health (Fig. 2). Theses mycooxins are not only locally toxic for the intestine, but also dysregulate many intestinal functions and impair the local immune response. This results in systemic toxicity leading to many symptoms, alteration of zootechnical parameters. Feed contamination with mycotoxins also increases impair the barrier function of the intestine, leading to translocation of bacteria across the intestine and thus intestinal and systemic infections.
Fig. 2

Summary of the intestinal toxicity of the main mycotoxins present in feed pig. DON and FB1 can induce several effects on the intestine, with at the end a global impact on the pig intestinal health

Global surveys indicate that animals are generally exposed to more than one mycotoxin [81]. Indeed fungi are able to produce several mycotoxins simultaneously; and it is common practice to use multiple grains in animal diets. Unfortunately, the toxicity of mycotoxin mixtures cannot be predicted based on their individual toxicities. Interactions between concomitantly occurring mycotoxins can be antagonistic, additive, or synergistic [82]. The data on combined toxicity of mycotoxins are limited and therefore, the health risk from exposure to a combination of mycotoxins is incompletely understood [83, 84] and deserves further investigation.

Abbreviations

AFB1, Aflatoxin B1; AFB2, Aflatoxin B2; CE-SSCP, Capillary Electrophoresis Single-Stranded Conformation Polymorphism; DNA, Deoxyribonucleic acid; DON, Deoxynivalenol; ERK 1/2, Extracellular Signal Regulated Kinase 1 and 2; FB1, Fumonisin B1; FoxP3, Forkhead box P3; HT2, HT2 toxin; IARC, International Agency for Research on Cancer; Ig, Imunoglobulin; IL, Interleukin; IPEC-J2, Porcine Intestinal Epithelial Cell line derived from the jejunum; JNK, C-Jun N-terminal Kinase; MAPKs, Mitogen Activated Protein Kinases; MCP1, Monocyte chemoattractant protein-1; MHC-II, Major Histocompatibility Complex - Class II; OTA, Ochratoxin A; OVA, Ovalbumin; PPE, porcine pulmonary edema ; PTC, Peptidyl Transferase Center; RALDH1, Retinaldehyde dehydrogenase 1; RNA, Ribonucleic acid; Sa, Sphinganine; SGLT-1, Sodium-glucose dependent transporter; So, Sphingosine; STAT3, Signal transducer and activator of transcription 3; T2, T2 toxin; TEER, Trans Epithelial Electrical Resistance; TGF, Transforming Growth Factor; TNF, Tumor Necrosis Factor; ZEN, Zearalenone

Declarations

Acknowledgment

The authors thank Ryan Hines, Biomin, for language editing.

Funding

A. Pierron was supported by a fellowship from CIFRE (2012/0572, jointly financed by the BIOMIN Holding GmbH, Association Nationale de la Recherche Technique and INRA). This work was supported in part by the projects Liporeg (APP-ICSA 2015) and PHC STEFANIK 2016.

Availability of data and materials

Not applicable.

Authors’ contributions

All authors agree fully to the content of the review. All authors read and approved the final manuscript.

Author’s information

IPO, Research director at INRA Toxalim, Head of the team “Biosynthesis and Toxicity of Mycotoxins”.

AP, 3rd year PhD student at INRA Toxalim, in the team “Biosynthesis and Toxicity of Mycotoxins”.

IAK is a postdoctoral research fellow in the INRA Toxalim team “Biosynthesis and Toxicity of Mycotoxins”.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
ToxAlim Research Centre in Food Toxicology, INRA, UMR 1331, ENVT, INP Purpan
(2)
BIOMIN Research Center

References

  1. Hazel CM, Patel S. Influence of processing on trichothecene levels. Toxicol Lett. 2004;153:51–9.View ArticlePubMedGoogle Scholar
  2. Bryden WL. Mycotoxin contamination of the feed supply chain : Implications for animal productivity and feed security. Anim Feed Sci Technol. 2012;173:134–58.View ArticleGoogle Scholar
  3. Maresca M, Fantini J. Some food-associated mycotoxins as potential risk factors in humans predisposed to chronic intestinal inflammatory diseases. Toxicon. 2010;56:282–94.View ArticlePubMedGoogle Scholar
  4. CAST. Potential economic costs of mycotoxins in United States. In: Task Force Report 138. Mycotoxins: Risks in plant, animal and human systems. Ames: Council for Agricultural Science and Technology; 2003. p. 136–42.Google Scholar
  5. Maresca M. From the gut to the brain: journey and pathophysiological effects of the food-associated mycotoxin Deoxynivalenol. Toxins. 2013;5:784–820.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Pestka JJ. Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance. Arch Toxicol. 2010;84(9):663–79.View ArticlePubMedGoogle Scholar
  7. Wang Z, Wu Q, Kuca K, Dohnal V, Tian Z. Deoxynivalenol: signaling pathways and human exposure risk assessment--an update. Arch Toxicol. 2014;88(11):1915–28.View ArticlePubMedGoogle Scholar
  8. Garreau de Loubresse N, Prokhorova I, Holtkamp W, Rodnina MV, Yusupova G, Yusupov M. Structural basis for the inhibition of the eukaryotic ribosome. Nature. 2014;513(7519):517–22.View ArticlePubMedGoogle Scholar
  9. Pierron A, Mimoun S, Murate LS, Loiseau N, Lippi Y, Bracarense A-PFL, et al. Microbial biotransformation of DON: molecular basis for reduced toxicity. Sci Rep. 2016;6:29105.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Pestka JJ. Deoxynivalenol-induced proinflammatory gene expression: mechanisms and pathological sequelae. Toxins (Basel). 2010;2(6):1300–17.View ArticleGoogle Scholar
  11. Pestka JJ, Smolinski AT. Deoxynivalenol: toxicology and potential effects on humans. J Toxicol Environ Health B Crit Rev. 2005;8:39–69.View ArticlePubMedGoogle Scholar
  12. Haschek WM, Voss KA, Beasley V. Selected mycotoxins affecting animal and human health. In: Haschek WM, Rousseaux CG, Wallig MA, editors. Handbook of Toxicological Pathology. New York: Academic; 2002. p. 645–99.View ArticleGoogle Scholar
  13. Vesonder RF, Ciegler A, Jensen AH. Isolation of the emetic principle from Fusarium-infected corn. Appl Microbiol. 1973;26:1008–10.PubMedPubMed CentralGoogle Scholar
  14. Lebrun B, Tardivel C, Felix B, Abysique A, Troadec JD, Gaige S, et al. Dysregulation of energy balance by trichothecene mycotoxins: Mechanisms and prospects. Neurotoxicology. 2015;49:15–27.View ArticlePubMedGoogle Scholar
  15. Sobrova P, Adam V, Vasatkova A, Beklova M, Zeman L, Kizek R. Deoxynivalenol and its toxicity. Interdiscip Toxicol. 2010;3:94–9.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Sun XM, Zhang XH, Wang HY, Cao WJ, Yan X, Zuo LF, et al. Effects of sterigmatocystin, deoxynivalenol and aflatoxin G1 on apoptosis of human peripheral blood lymphocytes in vitro. Biomed Environ Sci. 2002;15:145–52.PubMedGoogle Scholar
  17. Escriva L, Font G, Manyes L. In vivo toxicity studies of fusarium mycotoxins in the last decade: a review. Food Chem Toxicol. 2015;78:185–206.View ArticlePubMedGoogle Scholar
  18. Voss KA, Smith GW, Haschek WM. Fumonisins: Toxicokinetics, mechanism of action and toxicity. Anim Feed Sci Tech. 2007;137:299–325.View ArticleGoogle Scholar
  19. Howard PC, Couch LH, Patton RE, Eppley RM, Doerge DR, Churchwell MI, et al. Comparison of the toxicity of several fumonisin derivatives in a 28-day feeding study with female B6C3F(1) mice. Toxicol Appl Pharm. 2002;185:153–65.View ArticleGoogle Scholar
  20. Grenier B, Bracarense AP, Schwartz HE, Trumel C, Cossalter AM, Schatzmayr G, et al. The low intestinal and hepatic toxicity of hydrolyzed fumonisin B1 correlates with its inability to alter the metabolism of sphingolipids. Biochem Pharmacol. 2012;83:1465–73.View ArticlePubMedGoogle Scholar
  21. Enongene EN, Sharma RP, Bhandari N, Miller JD, Meredith FI, Voss KA, et al. Persistence and reversibility of the elevation in free sphingoid bases induced by fumonisin inhibition of ceramide synthase. Toxicol Sci. 2002;67:173–81.View ArticlePubMedGoogle Scholar
  22. Voss KA, Plattner RD, Riley RT, Meredith FI, Norred WP. In vivo effects of fumonisin B(1)-producing and fumonisin B(1)-nonproducing Fusarium moniliforme isolates are similar: Fumonisins B(2) and B(3) cause hepato- and nephrotoxicity in rats. Mycopathologia. 1998;141:45–58.View ArticlePubMedGoogle Scholar
  23. Gumprecht LA, Beasley VR, Weigel RM, Parker HM, Tumbleson ME, Bacon CW, et al. Development of fumonisin-induced hepatotoxicity and pulmonary edema in orally dosed swine: morphological and biochemical alterations. Toxicol Pathol. 1998;26:777–88.View ArticlePubMedGoogle Scholar
  24. Gumprecht LA, Marcucci A, Weigel RM, Vesonder RF, Riley RT, Showker JL, et al. Effects of intravenous fumonisin B1 in rabbits: nephrotoxicity and sphingolipid alterations. Nat Toxins. 1995;3:395–403.View ArticlePubMedGoogle Scholar
  25. Stevens VL, Tang J. Fumonisin B1-induced sphingolipid depletion inhibits vitamin uptake via the glycosylphosphatidylinositol-anchored folate receptor. J Biol Chem. 1997;272:18020–5.View ArticlePubMedGoogle Scholar
  26. Gelineau-van Waes J, Starr L, Maddox J, Aleman F, Voss KA, Wilberding J, et al. Maternal fumonisin exposure and risk for neural tube defects: mechanisms in an in vivo mouse model. Birth Defects Res A Clin Mol Teratol. 2005;73:487–97.View ArticlePubMedGoogle Scholar
  27. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr. 2007;85:285S–8.PubMedGoogle Scholar
  28. Prelusky DB, Trenholm HL, Rotter BA, Miller JD, Savard ME, Yeung JM, et al. Biological fate of fumonisin B1 in food-producing animals. Adv Exp Med Biol. 1996;392:265–78.View ArticlePubMedGoogle Scholar
  29. Prelusky DB, Trenholm HL, Savard ME. Pharmacokinetic fate of 14C-labelled fumonisin B1 in swine. Nat Toxins. 1994;2:73–80.View ArticlePubMedGoogle Scholar
  30. Osweiler GD, Ross PF, Wilson TM, Nelson PE, Witte ST, Carson TL, et al. Characterization of an Epizootic of Pulmonary-Edema in Swine Associated with Fumonisin in Corn Screenings. J Vet Diagn Invest. 1992;4:53–9.View ArticlePubMedGoogle Scholar
  31. Haschek WM, Motelin G, Ness DK, Harlin KS, Hall WF, Vesonder RF, et al. Characterization of Fumonisin Toxicity in Orally and Intravenously Dosed Swine. Mycopathologia. 1992;117:83–96.View ArticlePubMedGoogle Scholar
  32. Zomborszky-Kovacs M, Vetesi FF, Kovacs F, Bata A, Toth A, Tornyos G. Preliminary communication: Examination of the harmful effect to fetuses of fumonisin B-1 in pregnant sows. Teratogen Carcin Mut. 2000;20:293–9.View ArticleGoogle Scholar
  33. Constable PD, Smith GW, Rottinghaus GE, Tumbleson ME, Haschek WM. Fumonisin-induced blockade of ceramide synthase in sphingolipid biosynthetic pathway alters aortic input impedance spectrum of pigs. Am J Physiol Heart Circ Physiol. 2003;284:H2034–44.View ArticlePubMedGoogle Scholar
  34. Smith GW, Constable PD, Tumbleson ME, Rottinghaus GE, Haschek WM. Sequence of cardiovascular changes leading to pulmonary edema in swine fed culture material containing fumonisin. Am J Vet Res. 1999;60:1292–300.PubMedGoogle Scholar
  35. Smith GW, Constable PD, Foreman JH, Eppley RM, Waggoner AL, Tumbleson ME, et al. Cardiovascular changes associated with intravenous administration of fumonisin B-1 in horses. Am J Vet Res. 2002;63:538–45.View ArticlePubMedGoogle Scholar
  36. Casteel SW, Turk JR, Cowart RP, Rottinghaus GE. Chronic Toxicity of Fumonisin in Weanling Pigs. J Vet Diagn Invest. 1993;5:413–7.View ArticlePubMedGoogle Scholar
  37. Harvey RB, Edrington TS, Kubena LF, Elissalde MH, Rottinghaus GE. Influence of Aflatoxin and Fumonisin B-1-Containing Culture Material on Growing Barrows. Am J Vet Res. 1995;56:1668–72.PubMedGoogle Scholar
  38. Haschek WM, Gumprecht LA, Smith G, Tumbleson ME, Constable PD. Fumonisin toxicosis in swine: an overview of porcine pulmonary edema and current perspectives. Environ Health Perspect. 2001;109 Suppl 2:251–7.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Smith GW, Constable PD, Haschek WM. Cardiovascular responses to short-term fumonisin exposure in swine. Fund Appl Toxicol. 1996;33:140–8.View ArticleGoogle Scholar
  40. Marin DE, Gouze ME, Taranu I, Oswald IP. Fumonisin B1 alters cell cycle progression and interleukin-2 synthesis in swine peripheral blood mononuclear cells. Mol Nutr Food Res. 2007;51:1406–12.View ArticlePubMedGoogle Scholar
  41. Marin DE, Taranu I, Pascale F, Lionide A, Burlacu R, Bailly JD, et al. Sex-related differences in the immune response of weanling piglets exposed to low doses of fumonisin extract. Br J Nutr. 2006;95:1185–92.View ArticlePubMedGoogle Scholar
  42. Johnson VJ, Sharma RP. Gender-dependent immunosuppression following subacute exposure to fumonisin B1. Int Immunopharmacol. 2001;1:2023–34.View ArticlePubMedGoogle Scholar
  43. Bryden WL. Mycotoxins in the food chain: human health implications. Asia Pac J Clin Nutr. 2007;16 Suppl 1:95–101.PubMedGoogle Scholar
  44. Wild CP. Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food Nutr Bull. 2007;28(2 Suppl):S372–80.View ArticlePubMedGoogle Scholar
  45. Andretta I, Kipper M, Lehnen CR, Hauschild L, Vale MM, Lovatto PA. Meta-analytical study of productive and nutritional interactions of mycotoxins in growing pigs. Animal. 2012;6:1476–82.View ArticlePubMedGoogle Scholar
  46. Prelusky DB. A study on the effect of deoxynivalenol on serotonin receptor binding in pig brain membranes. J Environ Sci Health B. 1996;31:1103–17.View ArticlePubMedGoogle Scholar
  47. Bouhet S, Oswald IP. The effects of mycotoxins, fungal food contaminants, on the intestinal epithelial cell-derived innate immune response. Vet Immunol Immunopathol. 2005;108:199–209.View ArticlePubMedGoogle Scholar
  48. Oswald IP. Role of intestinal epithelial cells in the innate immune defence of the pig intestine. Vet Res. 2006;37:359–68.View ArticlePubMedGoogle Scholar
  49. Alassane-Kpembi I, Oswald IP. Effects of feed contaminants on the intestinal health of monogastric farm animals. In: Nieworld T, editor. Intestinal health: key to optimise production. Wageningen: Wageningen Academic Publishers; 2015. p. 169–90.Google Scholar
  50. Grenier B, Applegate TJ. Modulation of intestinal functions following mycotoxin ingestion: meta-analysis of published experiments in animals. Toxins (Basel). 2013;5:396–430.View ArticleGoogle Scholar
  51. Ghareeb K, Awad WA, Bohm J, Zebeli Q. Impacts of the feed contaminant deoxynivalenol on the intestine of monogastric animals: poultry and swine. J Appl Toxicol. 2015;35:327–37.View ArticlePubMedGoogle Scholar
  52. Bracarense AP, Lucioli J, Grenier B, Drociunas Pacheco G, Moll WD, Schatzmayr G, et al. Chronic ingestion of deoxynivalenol and fumonisin, alone or in interaction, induces morphological and immunological changes in the intestine of piglets. Br J Nutr. 2012;107:1776–86.View ArticlePubMedGoogle Scholar
  53. Bouhet S, Oswald IP. The intestine as a possible target for fumonisin toxicity. Mol Nutr Food Res. 2007;51:925–31.View ArticlePubMedGoogle Scholar
  54. Awad WA, Aschenbach JR, Setyabudi FM, Razzazi-Fazeli E, Bohm J, Zentek J. In vitro effects of deoxynivalenol on small intestinal D-glucose uptake and absorption of deoxynivalenol across the isolated jejunal epithelium of laying hens. Poult Sci. 2007;86:15–20.View ArticlePubMedGoogle Scholar
  55. Dietrich B, Neuenschwander S, Bucher B, Wenk C. Fusarium mycotoxin-contaminated wheat containing deoxynivalenol alters the gene expression in the liver and the jejunum of broilers. Animal. 2012;6:278–91.View ArticlePubMedGoogle Scholar
  56. Lessard M, Boudry G, Seve B, Oswald IP, Lalles JP. Intestinal physiology and peptidase activity in male pigs are modulated by consumption of corn culture extracts containing fumonisins. J Nutr. 2009;139:1303–7.View ArticlePubMedGoogle Scholar
  57. Lalles JP, Lessard M, Boudry G. Intestinal barrier function is modulated by short-term exposure to fumonisin B(1) in Ussing chambers. Vet Res Commun. 2009;33:1039–43.View ArticlePubMedGoogle Scholar
  58. Loiseau N, Debrauwer L, Sambou T, Bouhet S, Miller JD, Martin PG, et al. Fumonisin B1 exposure and its selective effect on porcine jejunal segment: sphingolipids, glycolipids and trans-epithelial passage disturbance. Biochem Pharmacol. 2007;74:144–52.View ArticlePubMedGoogle Scholar
  59. Eriksen GS, Pettersson H. Toxicological evaluation of trichothecenes in animal feed. Anim Feed Sci Technol. 2004;114:205–39.View ArticleGoogle Scholar
  60. Pinton P, Oswald IP. Effect of deoxynivalenol and other Type B trichothecenes on the intestine: a review. Toxins (Basel). 2014;6:1615–43.View ArticleGoogle Scholar
  61. Lucioli J, Pinton P, Callu P, Laffitte J, Grosjean F, Kolf-Clauw M, et al. The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: Interest of ex vivo models as an alternative to in vivo experiments. Toxicon. 2013;66:31–6.View ArticlePubMedGoogle Scholar
  62. Kolf-Clauw M, Castellote J, Joly B, Bourges-Abella N, Raymond-Letron I, Pinton P, et al. Development of a pig jejunal explant culture for studying the gastrointestinal toxicity of the mycotoxin deoxynivalenol: Histopathological analysis. Toxicol In Vitro. 2009;23:1580–4.View ArticlePubMedGoogle Scholar
  63. Yunus AW, Blajet-Kosicka A, Kosicki R, Khan MZ, Rehman H, Böhm J. Deoxynivalenol as a contaminant of broiler feed: intetsinal development, absorptive functionality, and metabolism of the mycotoxin. Poult Sci. 2012;91:852-61.Google Scholar
  64. Pierron A, Mimoun S, Murate LS, Loiseau N, Lippi Y, Bracarense AP, et al. Intestinal toxicity of the masked mycotoxin deoxynivalenol-3-beta-D-glucoside. Arch Toxicol. 2016;90:2037–46.View ArticlePubMedGoogle Scholar
  65. Pinton P, Nougayrede JP, Del Rio J-C, Moreno C, Marin DE, Ferrier L, et al. The food contaminant deoxynivalenol, decreases intestinal barrier permeability and reduces claudin expression. Toxicol Appl Pharmacol. 2009;237:41–8.View ArticlePubMedGoogle Scholar
  66. Goossens J, Pasmans F, Verbrugghe E, Vandenbroucke V, De Baere S, Meyer E, et al. Porcine intestinal epithelial barrier disruption by the Fusarium mycotoxins deoxynivalenol and T-2 toxin promotes transepithelial passage of doxycycline and paromomycin. BMC Vet Res. 2012;8:245.View ArticlePubMedPubMed CentralGoogle Scholar
  67. Bouhet S, Hourcade E, Loiseau N, Fikry A, Martinez S, Roselli M, et al. The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. Toxicol Sci. 2004;77:165–71.View ArticlePubMedGoogle Scholar
  68. Vandenbroucke V, Croubels S, Martel A, Verbrugghe E, Goossens J, Van Deun K, et al. The mycotoxin deoxynivalenol potentiates intestinal inflammation by Salmonella typhimurium in porcine ileal loops. PLoS One. 2011;6:e23871.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Devriendt B, Gallois M, Verdonck F, Wache Y, Bimczok D, Oswald IP, et al. The food contaminant fumonisin B(1) reduces the maturation of porcine CD11R1(+) intestinal antigen presenting cells and antigen-specific immune responses, leading to a prolonged intestinal ETEC infection. Vet Res. 2009;40(4):40.View ArticlePubMedPubMed CentralGoogle Scholar
  70. Oswald IP, Desautels C, Laffitte J, Fournout S, Peres SY, Odin M, et al. Mycotoxin fumonisin B1 increases intestinal colonization by pathogenic Escherichia coli in pigs. Appl Environ Microbiol. 2003;69:5870–4.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Bouhet S, Le Dorze E, Peres S, Fairbrother JM, Oswald IP. Mycotoxin fumonisin B1 selectively down-regulates the basal IL-8 expression in pig intestine: in vivo and in vitro studies. Food Chem Toxicol. 2006;44:1768–73.View ArticlePubMedGoogle Scholar
  72. Hoch RC, Schraufstatter IU, Cochrane CG. In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. J Lab Clin Med. 1996;128:134–45.View ArticlePubMedGoogle Scholar
  73. Zachrisson K, Neopikhanov V, Wretlind B, Uribe A. Mitogenic action of tumour necrosis factor-alpha and interleukin-8 on explants of human duodenal mucosa. Cytokine. 2001;15:148–55.View ArticlePubMedGoogle Scholar
  74. Maheshwari A, Lacson A, Lu W, Fox SE, Barleycorn AA, Christensen RD, et al. Interleukin-8/CXCL8 forms an autocrine loop in fetal intestinal mucosa. Pediatr Res. 2004;56:240–9.View ArticlePubMedGoogle Scholar
  75. Maresca M, Yahi N, Younes-Sakr L, Boyron M, Caporiccio B, Fantini J. Both direct and indirect effects account for the pro-inflammatory activity of enteropathogenic mycotoxins on the human intestinal epithelium: stimulation of interleukin-8 secretion, potentiation of interleukin-1beta effect and increase in the transepithelial passage of commensal bacteria. Toxicol Appl Pharmacol. 2008;228:84–92.View ArticlePubMedGoogle Scholar
  76. Cano PM, Seeboth J, Meurens F, Cognie J, Abrami R, Oswald IP, et al. Deoxynivalenol as a new factor in the persistence of intestinal inflammatory diseases: an emerging hypothesis through possible modulation of Th17-mediated response. PLoS One. 2013;8:e53647.View ArticlePubMedPubMed CentralGoogle Scholar
  77. Ali-Vehmas T, Rizzo A, Westermarck T, Atroshi F. Measurement of antibacterial activities of T-2 toxin, deoxynivalenol, ochratoxin A, aflatoxin B1 and fumonisin B1 using microtitration tray-based turbidimetric techniques. Zentralbl Veterinarmed A. 1998;45:453–8.View ArticlePubMedGoogle Scholar
  78. Burmeister HR, Hesseltine CW. Survey of the sensitivity of microorganisms to aflatoxin. Appl Microbiol. 1966;14:403–4.PubMedPubMed CentralGoogle Scholar
  79. Wache YJ, Valat C, Postollec G, Bougeard S, Burel C, Oswald IP, et al. Impact of deoxynivalenol on the intestinal microflora of pigs. Int J Mol Sci. 2009;10:1–17.View ArticlePubMedGoogle Scholar
  80. Burel C, Tanguy M, Guerre P, Boilletot E, Cariolet R, Queguiner M, et al. Effect of low dose of fumonisins on pig health: immune status, intestinal microbiota and sensitivity to Salmonella. Toxins (Basel). 2013;5:841–64.View ArticleGoogle Scholar
  81. Streit E, Schatzmayr G, Tassis P, Tzika E, Marin D, Taranu I, et al. Current situation of mycotoxin contamination and co-occurrence in animal feed--focus on Europe. Toxins (Basel). 2012;4:788–809.View ArticleGoogle Scholar
  82. Alassane-Kpembi I, Puel O, Oswald IP. Toxicological interactions between the mycotoxins deoxynivalenol, nivalenol and their acetylated derivatives in intestinal epithelial cells. Arch Toxicol. 2015;89:1337–46.View ArticlePubMedGoogle Scholar
  83. Grenier B, Oswald IP. Mycotoxin co-contamination of foods and feeds: meta-analysis of publications describing toxicological interactions. World Mycotoxin J. 2011;4:285–313.View ArticleGoogle Scholar
  84. Alassane-Kpembi I, Schatzmayr G, Taranu I, Marin D, Puel O, Oswald IP. Mycotoxins co-contamination: Methodological aspects and biological relevance of combined toxicity studies. Crit Rev Food Sci Nutr. 2016. In press.Google Scholar

Copyright

© The Author(s). 2016

Advertisement